Immune Therapeutics (IMUN) Short Interest Ratio & Short Volume

Short interest is the volume of Immune Therapeutics shares that have been sold short but have not yet been closed out or covered. As of October 15th, investors have sold 300 shares of IMUN short. Learn More on Immune Therapeutics' current short interest.

Here is how the short interest of companies in the sector of "medical" compare to Immune Therapeutics: Bionomics Limited (2.03%), Pulmatrix, Inc. (0.32%), Clever Leaves Holdings Inc. (0.61%), ASLAN Pharmaceuticals Limited (1.47%), Lixte Biotechnology Holdings, Inc. (4.59%), Theriva Biologics, Inc. (2.35%), Pasithea Therapeutics Corp. (1.34%), TFF Pharmaceuticals, Inc. (2.77%), Chemomab Therapeutics Ltd. (1.31%), Trevena, Inc. (0.33%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($3.82 billion), T-Mobile US, Inc. ($3.69 billion), Occidental Petroleum Co. ($2.90 billion), TC Energy Co. ($2.74 billion), Tractor Supply ($2.28 billion), Rivian Automotive, Inc. ($1.92 billion), Moderna, Inc. ($1.77 billion), Celsius Holdings, Inc. ($1.72 billion), Coinbase Global, Inc. ($1.66 billion), and Royal Caribbean Cruises Ltd. ($1.65 billion). View all of the most shorted stocks.

Short selling IMUN is an investing strategy that aims to generate trading profit from Immune Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Immune Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IMUN, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IMUN, twice per month. The most recent reporting period available is October, 15 2023.